LWCFA
TNDM icon

Loring Wolcott & Coolidge Fiduciary Advisors’s Tandem Diabetes Care TNDM Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio TNDM Stock Details TNDM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-400
Closed -$31K – 616
2016
Q3 		$31K Buy
+400
New +$29.2K ﹤0.01% 444

Other funds holding TNDM

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's TNDM Position: Q4 2016 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Tandem Diabetes Care (TNDM) in Q4 2016, closing a stake of 400 shares — an estimated $31K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in TNDM in Q3 2016 and held it in 1 quarter. The position peaked at $31K in Q3 2016. 75 funds tracked by Wall St. Rank hold TNDM as of Q4 2016.

  • Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Tandem Diabetes Care position as of Q4 2016 after selling out during the quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors sold 400 Tandem Diabetes Care shares in Q4 2016, an estimated $31K.
  • Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Tandem Diabetes Care in Q3 2016 and held it in 1 quarter.
  • Loring Wolcott & Coolidge Fiduciary Advisors's Tandem Diabetes Care position peaked at $31K in Q3 2016.
  • 75 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q4 2016.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2016, filed 2 Feb 2017.